Short answer
Protalix BioTherapeutics, Inc. (PLX) filed an 8-K current report with the SEC on June 25, 2026 reporting Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders elected all eight director nominees, maintaining board continuity; Amos Bar Shalev received the highest withheld vote count at 6,461,724.
Protalix BioTherapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Stockholders elected all eight director nominees, maintaining board continuity; Amos Bar Shalev received the highest withheld vote count at 6,461,724
- Executive compensation approved on advisory basis, with 28,368,614 votes for and 6,683,937 against
- Incentive plan expanded by 3,500,000 shares to 20,975,171, increasing potential equity dilution and employee retention capacity
- Kesselman & Kesselman ratified as fiscal-year 2026 auditor, with 42,958,243 votes for and 2,001,734 against
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Protalix BioTherapeutics, Inc. 8-K filings
Get the next PLX 8-K as it lands
Follow PLX for push alerts, or ask the research agent what this filing means.